AU4474497A - Methods and means for selecting peptides and proteins having specific affinity for a target - Google Patents

Methods and means for selecting peptides and proteins having specific affinity for a target

Info

Publication number
AU4474497A
AU4474497A AU44744/97A AU4474497A AU4474497A AU 4474497 A AU4474497 A AU 4474497A AU 44744/97 A AU44744/97 A AU 44744/97A AU 4474497 A AU4474497 A AU 4474497A AU 4474497 A AU4474497 A AU 4474497A
Authority
AU
Australia
Prior art keywords
target
proteins
peptides
methods
specific affinity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU44744/97A
Inventor
Cornelis Adriaan De Kruif
Ton Logtenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
U Bisys BV
Original Assignee
U Bisys BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by U Bisys BV filed Critical U Bisys BV
Publication of AU4474497A publication Critical patent/AU4474497A/en
Assigned to U-BISYS B.V. reassignment U-BISYS B.V. Alteration of Name(s) of Applicant(s) under S113 Assignors: UNIVERSITEIT UTRECHT
Priority to AU11942/02A priority Critical patent/AU773394B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

The invention provides novel methods and means for selecting peptides and for other proteinaceous molecules having specific binding affinity for a target. The binding peptides/proteins are displayed on replicable display packages, preferably phages. The binding peptides are tested for this binding affinity to the target. In one embodiment, the target is provided in the form of peptides displayed on a solid phase, in another the target is presented in a tissue section.
AU44744/97A 1996-10-08 1997-10-07 Methods and means for selecting peptides and proteins having specific affinity for a target Abandoned AU4474497A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU11942/02A AU773394B2 (en) 1996-10-08 2002-01-18 Methods and means for selecting peptides and proteins having specific affinity for a target

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP96202791 1996-10-08
EP96202791 1996-10-08
PCT/NL1997/000557 WO1998015833A1 (en) 1996-10-08 1997-10-07 Methods and means for selecting peptides and proteins having specific affinity for a target

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU11942/02A Division AU773394B2 (en) 1996-10-08 2002-01-18 Methods and means for selecting peptides and proteins having specific affinity for a target

Publications (1)

Publication Number Publication Date
AU4474497A true AU4474497A (en) 1998-05-05

Family

ID=8224468

Family Applications (1)

Application Number Title Priority Date Filing Date
AU44744/97A Abandoned AU4474497A (en) 1996-10-08 1997-10-07 Methods and means for selecting peptides and proteins having specific affinity for a target

Country Status (9)

Country Link
EP (1) EP0934526B1 (en)
JP (1) JP2001512560A (en)
AT (1) ATE230850T1 (en)
AU (1) AU4474497A (en)
CA (1) CA2267139A1 (en)
DE (1) DE69718341T2 (en)
DK (1) DK0934526T3 (en)
ES (1) ES2190543T3 (en)
WO (1) WO1998015833A1 (en)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750373A (en) * 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
WO1999006833A1 (en) * 1997-07-29 1999-02-11 Huston James S Methods for obtaining probes of peptide function
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
DE19802576B4 (en) * 1998-01-23 2004-10-28 Xerion Pharmaceuticals Ag Methods for the simultaneous identification of proteins and their binding partners
CA2334170A1 (en) 1998-07-27 2000-02-10 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
CA2361877A1 (en) 1999-03-01 2000-09-08 Genentech, Inc. Antibodies for cancer therapy and diagnosis
ATE346162T1 (en) * 1999-04-14 2006-12-15 Us Gov Health & Human Serv HIGHLY SENSITIVE DETECTION OF BIOMOLECULES USING ßPHAGE DISPLAYß
EP1179186B1 (en) 1999-05-14 2006-01-11 McGill University Method for identifying modulators of interacting proteins
EP1684077A1 (en) * 1999-05-14 2006-07-26 McGill University Method for identifying modulators of interacting proteins
DE60033455T2 (en) * 1999-12-27 2007-11-29 Crucell Holland B.V. Human monoclonal antibody to Ep-CAM and its use in cancer therapy
WO2001048478A1 (en) * 1999-12-27 2001-07-05 Toray Industries, Inc. Cytokine-like peptide
DE10009341A1 (en) * 2000-02-22 2001-09-06 Florian Kern Method for antigen-specific stimulation of T lymphocytes
SE0000597D0 (en) * 2000-02-24 2000-02-24 Active Biotech Ab Novel antibody
CA2401367A1 (en) * 2000-02-25 2001-08-30 Crucell Holland B.V. Activated vitronectin as a marker of angiogenesis detected with phage antibodies
EP1130099A1 (en) * 2000-02-25 2001-09-05 Crucell Holland B.V. Activated vitronectin as a marker of angiogenesis detected with phage antibodies
LT2857516T (en) 2000-04-11 2017-09-11 Genentech, Inc. Multivalent antibodies and uses therefor
US6743778B2 (en) 2000-04-21 2004-06-01 Amgen Inc. Apo-AI/AII peptide derivatives
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
EP1174440A1 (en) * 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
EP1303293B1 (en) 2000-07-27 2008-12-03 Genentech, Inc. Sequential administration of cpt-11 and apo-2l polypeptide
FR2821856B1 (en) * 2001-03-09 2003-12-26 Didier Elmlinger METHOD FOR CROSS SCREENING OF A DNA EXPRESSION BANK AND A TARGET OF TARGET MOLECULES ISOLATED ON A MEDIUM FOR THE SIMULTANEOUS COMPARISON OF THE AFFINITY AND SELECTIVITY OF THEIR INTERACTIONS
HU229910B1 (en) 2001-05-11 2014-12-29 Amgen Inc Thousand Oaks Peptides and related molecules that bind to tall-1
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
ES2372321T3 (en) 2001-06-20 2012-01-18 Genentech, Inc. COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF A LUNG TUMOR.
US20040241688A1 (en) * 2001-07-19 2004-12-02 Cuneyt Bukusoglu Human tissue specific drug screening procedure
ATE486092T1 (en) 2001-09-18 2010-11-15 Genentech Inc COMPOSITIONS AND METHODS FOR THE DIAGNOSIS OF TUMORS
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US20030228319A1 (en) 2002-04-16 2003-12-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2002367318B2 (en) 2002-01-02 2007-07-12 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003239966B9 (en) 2002-06-03 2010-08-26 Genentech, Inc. Synthetic antibody phage libraries
DE60317677T2 (en) 2002-06-13 2008-10-30 Crucell Holland B.V. OX40 (= CD134) RECEPTOR AGONISTS AND THERAPEUTIC USES
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
PT1523496E (en) 2002-07-18 2011-09-29 Merus B V PRODUCTION OF RECOMBINANT ANTIBODY MIXTURES
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
CA2505994A1 (en) 2002-11-15 2004-06-03 Chiron Corporation Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
CA2527694C (en) 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs
WO2005000894A2 (en) 2003-06-25 2005-01-06 Crucell Holland B.V. Binding molecules for the treatment of myeloid cell malignancies
MXPA06000347A (en) 2003-07-08 2006-03-28 Genentech Inc Il-17 a/f heterologous polypeptides and therapeutic uses thereof.
AU2004291141B2 (en) 2003-11-17 2009-06-11 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
AU2005205412B2 (en) 2004-01-20 2011-08-11 Merus N.V. Mixtures of binding proteins
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
AU2011218688B2 (en) * 2004-05-27 2013-01-10 Crucell Holland B.V. Binding molecules capable of neutralizing rabies virus and uses thereof
PT2314621E (en) * 2004-05-27 2014-06-23 Crucell Holland Bv Binding molecules capable of neutralizing rabies virus and uses thereof
WO2006010057A2 (en) 2004-07-08 2006-01-26 Amgen Inc. Therapeutic peptides
PL1781315T3 (en) 2004-08-23 2015-08-31 Yeda Res & Dev Peptide inhibitors for mediating stress responses
AU2005289685B2 (en) 2004-09-24 2009-07-16 Amgen Inc. Modified Fc molecules
AU2005293560B2 (en) 2004-10-12 2011-10-06 Crucell Holland B.V. Binding molecules for treatment and detection of cancer
SG159542A1 (en) 2004-11-11 2010-03-30 Crucell Holland Bv Compositions against sars-coronavirus and uses thereof
US8022040B2 (en) 2004-11-29 2011-09-20 The Regents Of The University Of California Hydroxyapatite-binding peptides for bone growth and inhibition
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
EP1869076A2 (en) 2005-03-10 2007-12-26 Genentech, Inc. Methods and compositions for modulating vascular integrity
ATE507242T1 (en) 2005-05-12 2011-05-15 Crucell Holland Bv HOST CELL-SPECIFIC BINDING MOLECULES CAPABILITY OF NEUTRALIZING VIRUSES AND APPLICATIONS THEREOF
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
AU2006290736B2 (en) 2005-09-15 2011-09-15 Crucell Holland B.V. Method for preparing immunoglobulin libraries
AU2006344395B2 (en) 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
DE602007009954D1 (en) 2006-03-22 2010-12-02 Viral Logic Systems Technology METHOD FOR IDENTIFYING POLYPEPTIDE TARGETS
US8129334B2 (en) 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
CA2647277A1 (en) 2006-04-05 2007-11-08 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
JP5586952B2 (en) 2006-06-06 2014-09-10 クルセル ホランド ベー ヴェー Human binding molecules having killing activity against enterococci and methods of use thereof
MX2008014977A (en) 2006-06-06 2008-12-05 Crucell Holland Bv Human binding molecules having killing activity against staphylococci and uses thereof.
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
JP5244103B2 (en) 2006-08-09 2013-07-24 ホームステッド クリニカル コーポレイション Organ-specific protein and method of use thereof
DK2059532T3 (en) 2006-09-07 2013-03-18 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
MY170607A (en) 2006-09-07 2019-08-20 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
EP2083017A4 (en) 2006-09-14 2011-01-12 Med & Biological Lab Co Ltd Antibody having enhanced adcc activity and method for production thereof
CN101557799B (en) 2006-12-05 2012-08-22 克鲁塞尔荷兰公司 Liquid anti-rabies antibody formulations
DK2436781T3 (en) 2007-02-22 2016-01-11 Genentech Inc Methods for the detection of inflammatory bowel disease
EP2137308B1 (en) 2007-03-26 2016-08-03 Agenus Inc. Cell surface display, screening and production of proteins of interest
CA2711826C (en) 2008-01-25 2018-02-27 Amgen Inc. Ferroportin antibodies and methods of use
US9315577B2 (en) 2008-05-01 2016-04-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
EP2319869B1 (en) 2008-06-20 2016-08-17 National University Corporation Okayama University ANTIBODY AGAINST OXIDIZED LDL/ß²GPI COMPLEX AND USE OF THE SAME
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
US9182406B2 (en) 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
WO2010130636A1 (en) 2009-05-11 2010-11-18 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
CN102459591B (en) 2009-05-20 2015-05-13 诺维莫尼公司 Systhetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
BR112012009409A2 (en) 2009-10-22 2017-02-21 Genentech Inc method of identifying an inhibitory substance, antagonist molecule, isolated nucleic acid, vector, host cell, method of making the molecule, composition, article of manufacture, method of inhibiting a biological activity, method of treating a pathological condition, method for detect msp in a sample and method to detect hepsin in a sample
SG10201408598XA (en) 2009-11-30 2015-02-27 Genentech Inc Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
NZ601293A (en) 2010-02-23 2014-10-31 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
RU2636461C2 (en) 2010-05-03 2017-11-23 Дженентек, Инк. Compositions and methods for diagnosis and treatment of tumour
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
US20140088019A1 (en) 2011-02-11 2014-03-27 Zyngenia, Inc. Monovalent and Multivalent Multispecific Complexes and Uses Thereof
GB2503604B (en) 2011-03-21 2020-04-22 Biodesy Llc Classification of kinase inhibitors using second harmonic optical techniques
WO2012160563A2 (en) 2011-05-23 2012-11-29 Yeda Research And Development Co. Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
ES2704038T3 (en) 2011-05-24 2019-03-13 Zyngenia Inc Multivalent and monovalent multispecific complexes and their uses
JP5683752B2 (en) 2011-07-14 2015-03-11 クルセル ホランド ベー ヴェー Human binding molecule capable of neutralizing influenza A virus of strain group 1 and strain 2 and influenza B virus
BR112014005720A2 (en) 2011-09-15 2017-12-12 Genentech Inc method of selecting and / or identifying a usp1 antagonist, uaf1 antagonist and / or an id antagonist that promotes a change in the cellular fate of said method
WO2013056148A2 (en) 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
KR102055958B1 (en) 2011-12-22 2019-12-13 글리코미메틱스, 인크. E-selectin antagonist compounds, compositions, and methods of use
JP2015506944A (en) 2012-01-18 2015-03-05 ジェネンテック， インコーポレイテッド Methods of using FGF19 modifiers
SG11201404703WA (en) 2012-02-11 2014-09-26 Genentech Inc R-spondin translocations and methods using the same
US9139863B2 (en) 2012-03-16 2015-09-22 Genentech, Inc. Engineered conformationally-stabilized proteins
RU2014141018A (en) 2012-03-16 2016-05-10 Ф. Хоффманн-Ля Рош Аг METHODS OF TREATING MELANOMA WITH CANCER INHIBITORS
CN104254541A (en) 2012-03-16 2014-12-31 弗·哈夫曼-拉罗切有限公司 Engineered conformationally-stabilized proteins
CN107383197B (en) 2012-04-20 2021-12-10 美勒斯公司 Methods and means for producing immunoglobulin-like molecules
JP6302460B2 (en) 2012-04-25 2018-03-28 バイオデシー， インコーポレイテッド Methods for detecting allosteric modulators of proteins
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
US9867841B2 (en) 2012-12-07 2018-01-16 Glycomimetics, Inc. Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
EP2970952B1 (en) 2013-03-14 2018-07-11 Adagene Inc. An integrated system for library construction, affinity binder screening and expression thereof
PL2972373T3 (en) 2013-03-15 2020-03-31 F. Hoffmann-La Roche Ag Biomarkers and methods of treating conditions associated with PD-1 and PD-L1
WO2014144600A2 (en) 2013-03-15 2014-09-18 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
IL286427B2 (en) 2014-01-28 2024-08-01 Mayo Found Medical Education & Res BCL-2 ANTI-APOPTOTIC PROTEIN FAMILY MEMBERS inhibitors for the treatment of a non-cancerous disease or a disease of the eye
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
BR112016025040A2 (en) 2014-05-23 2018-02-20 Genentech, Inc. methods to determine mit biomarker expression, to treat cancer, to identify an individual with cancer, to predict whether an individual with cancer is more or less likely to respond effectively to treatment, to inhibit cell proliferation, and to treat nccrcc in an individual
CN114057857A (en) 2014-06-20 2022-02-18 豪夫迈·罗氏有限公司 CHAGASIN-based stent compositions, methods and applications
EP3237906B8 (en) 2014-12-23 2020-10-28 Bluelight Therapeutics, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
CN107708720A (en) 2015-04-06 2018-02-16 苏伯多曼有限责任公司 Polypeptide containing from the beginning binding structural domain and application thereof
CA2980189A1 (en) 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
JP2019534858A (en) 2016-09-09 2019-12-05 ジェネンテック， インコーポレイテッド Selective peptide inhibitor of FRIZZLED
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
EP3615569A1 (en) 2017-04-25 2020-03-04 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
EP3655430A1 (en) 2017-07-19 2020-05-27 The U.S.A. as represented by the Secretary, Department of Health and Human Services Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
MX2021007179A (en) 2018-12-20 2021-09-28 Ksq Therapeutics Inc SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROCESSING PROTEASE 1 (USP1).
CA3134016A1 (en) 2019-05-09 2020-11-12 Genentech, Inc. Methods of making antibodies
IL302352A (en) 2020-10-30 2023-06-01 Ksq Therapeutics Inc Solid-state forms of converted pyrazolopyrimidines and their uses
WO2023066881A1 (en) 2021-10-18 2023-04-27 Astrazeneca Ab Inhibition of map3k15 for treating and preventing diabetes
CN121079327A (en) 2023-05-12 2025-12-05 基因泰克公司 Methods and compositions for reducing antibody viscosity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2095735C (en) * 1990-11-07 2004-02-03 Smriti U. Mehta Monoclonal antibodies to hepatitis c virus and method for using same
DK1820858T3 (en) * 1991-03-01 2009-11-02 Dyax Corp Chimeric protein comprising microprotein with two or more disulfide bonds and embodiments thereof
WO1995015982A2 (en) * 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
SE9401650D0 (en) * 1994-05-11 1994-05-11 Lars Frykberg New way of identifying peptides and aids that can be used in the method

Also Published As

Publication number Publication date
JP2001512560A (en) 2001-08-21
DE69718341D1 (en) 2003-02-13
DE69718341T2 (en) 2003-10-30
EP0934526B1 (en) 2003-01-08
CA2267139A1 (en) 1998-04-16
ES2190543T3 (en) 2003-08-01
DK0934526T3 (en) 2003-05-05
EP0934526A1 (en) 1999-08-11
WO1998015833A1 (en) 1998-04-16
ATE230850T1 (en) 2003-01-15

Similar Documents

Publication Publication Date Title
AU4474497A (en) Methods and means for selecting peptides and proteins having specific affinity for a target
CA2282497A1 (en) In vitro peptide or protein expression library
EP1712623A3 (en) Selection of proteins using RNA-protein fusions
GB2338237A (en) In vitro peptide or protein expression library
AU1873199A (en) Method of identifying binding site domains that retain the capacity of binding to an epitope
CA2196419A1 (en) Improvements in or relating to binding proteins for recognition of dna
DE69703449D1 (en) NEUROACTIVE PEPTIDES
AU2421397A (en) Improving binding affinity of antigenic peptides for mhc molecules
AU3477295A (en) Modified proteins
EP0772773A4 (en) PEPTIDES ATTACHING TO Src SH3 AND THEIR METHODS OF ISOLATION AND USE
EP2305710A3 (en) Synthetic antibody phage libraries
EP0820295A4 (en) Modified lysine or arginine containing proteins and peptides
AU3186397A (en) Prion protein binding proteins and uses thereof
FR2755144B1 (en) SINGLE CHAIN ANTI-P53 ANTIBODY FRAGMENTS AND USE THEREOF
WO1999030165A3 (en) Processes for identifying a solvent condition suitable for determining a biophysical property of a protein
AU3623197A (en) Peptide reagent for the detection of human cytomegalovirus (cmv)
EP1027070A4 (en) CONJUGATED PEPTIDES BINDING TO STRESS PROTEINS
GB9816514D0 (en) Novel method
WO1998017626A3 (en) Positively charged non-natural amino acids, methods of making thereof, and use thereof in peptides
CA2260870A1 (en) Phytofluors as fluorescent labels
CA2176236A1 (en) Tyrosinase-activator protein fusion enzyme
CA2112701A1 (en) Proteins s polypeptides and uses thereof
AU2002358520A1 (en) Method for the selection and identification of peptide or protein molecules by means of phase display
CA2140091A1 (en) Peptides and antisera for detecting human cyclooxygenase-1 and cyclooxygenase-2
WO1998002557A3 (en) MAMMALIAN TNF-α CONVERTASES

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: U-BISYS B.V.

Free format text: THE FORMER OWNER WAS: UNIVERSITEIT UTRECHT

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted